Polar Asset Management Partners’s Cytokinetics CYTK Stock Holding History

Polar Asset Management Partners’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-3,900	Closed	-$211K	–	748
2024 Q2	$211K	Sell	3,900 -88,400	-96%	-$5.34M	﹤0.01%	452
2024 Q1	$6.47M	Buy	+92,300	New	+$7.14M	0.11%	155
2023 Q3	–	Sell	-190,400	Closed	-$6.21M	–	901
2023 Q2	$6.21M	Buy	+190,400	New	+$7.04M	0.11%	234
2022 Q2	–	Sell	-82,600	Closed	-$3.04M	–	1371
2022 Q1	$3.04M	Hold	82,600	–	–	0.03%	541
2021 Q4	$3.77M	Buy	82,600 +26,900	+48%	+$1.04M	0.04%	492
2021 Q3	$1.99M	Sell	55,700 -116,400	-68%	-$3.43M	0.02%	564
2021 Q2	$3.41M	Buy	+172,100	New	+$4.04M	0.03%	475

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Polar Asset Management Partners's CYTK Position: Q3 2024 in Review

Polar Asset Management Partners sold out of Cytokinetics (CYTK) in Q3 2024, closing a stake of 3,900 shares — an estimated $211K sold.

Polar Asset Management Partners first reported a position in CYTK in Q2 2021 and held it in 7 quarters. The position peaked at $6.47M in Q1 2024. 347 funds tracked by Wall St. Rank hold CYTK as of Q3 2024.

Polar Asset Management Partners reported no remaining Cytokinetics position as of Q3 2024 after selling out during the quarter.
Polar Asset Management Partners sold 3,900 Cytokinetics shares in Q3 2024, an estimated $211K.
Polar Asset Management Partners first reported a position in Cytokinetics in Q2 2021 and held it in 7 quarters.
Polar Asset Management Partners's Cytokinetics position peaked at $6.47M in Q1 2024.
347 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2024.

Based on Polar Asset Management Partners's 13F filing for Q3 2024, filed 14 Nov 2024.